To date, successful immune responses have been reported for mRNA vaccines against the SARS-CoV-2 S protein, with excellent humoral and cellular responses in patients with previous infection or pre-existing T-cell immunity (Sahin et al., 2020; Casado et al., 2021b). The gene discussed is PROS1; the disease is infection.